nature biotechnology l e t t e r s Effective therapies are needed to control excessive bleeding in a range of clinical conditions. We improve hemostasis in vivo using a conformationally pliant variant of coagulation factor Xa (FXa I16L ) rendered partially inactive by a defect in the transition from zymogen to active protease 1,2 . Using mouse models of hemophilia, we show that FXa I16L has a longer halflife than wild-type FXa and does not cause excessive activation of coagulation. Once clotting mechanisms are activated to produce its cofactor FVa, FXa I16L is driven to the protease state and restores hemostasis in hemophilic animals upon vascular injury. Moreover, using human or murine analogs, we show that FXa I16L is more efficacious than FVIIa, which is used to treat bleeding in hemophilia inhibitor patients 3 . FXa I16L may provide an effective strategy to enhance blood clot formation and act as a rapid pan-hemostatic agent for the treatment of bleeding conditions.
l e t t e r s Effective therapies are needed to control excessive bleeding in a range of clinical conditions. We improve hemostasis in vivo using a conformationally pliant variant of coagulation factor Xa (FXa I16L ) rendered partially inactive by a defect in the transition from zymogen to active protease 1, 2 . Using mouse models of hemophilia, we show that FXa I16L has a longer halflife than wild-type FXa and does not cause excessive activation of coagulation. Once clotting mechanisms are activated to produce its cofactor FVa, FXa I16L is driven to the protease state and restores hemostasis in hemophilic animals upon vascular injury. Moreover, using human or murine analogs, we show that FXa I16L is more efficacious than FVIIa, which is used to treat bleeding in hemophilia inhibitor patients 3 . FXa I16L may provide an effective strategy to enhance blood clot formation and act as a rapid pan-hemostatic agent for the treatment of bleeding conditions. The formation of a blood clot following vascular injury is a vital host defense mechanism. This process is compromised in individuals with congenital or acquired bleeding disorders such as hemophilia A (HA; factor VIII (FVIII) deficiency) and hemophilia B (HB; factor IX (FIX) deficiency) 4 . FVIII and FIX function in the intrinsic pathway of coagulation to maintain normal hemostasis by affecting the conversion of FX to FXa. Membrane-bound FXa in the presence of its cofactor FVa (prothrombinase complex) converts prothrombin to thrombin, which activates platelets and converts fibrinogen to fibrin to form the thrombus 5 . Management of patients with HA and HB has dramatically improved over the past three decades 6 . However, development of inhibitory neutralizing alloantibodies (inhibitors) in response to infusion of FVIII or FIX protein remains a serious threat to diseaserelated morbidity and mortality 7, 8 . Protein-based biopharmaceuticals that bypass the intrinsic pathway (bypassing agents), such as activated prothrombin complex concentrates (e.g., FEIBA) and recombinant FVIIa (e.g., NovoSeven), are viable strategies to re-establish hemostasis in these patients 3, 9 . However, neither is universally effective and neither can completely normalize thrombin generation, with some individuals experiencing a variable response to either of these two bypassing agents 10 . Furthermore, the need for frequent high-dose infusions to stop bleeding results in costly treatment 11 .
Existing bypassing strategies are directed toward enhancing FXa production to accelerate the formation of thrombin 12, 13 . FVIIa at pharmacological doses (90 µg/kg; 1.8 nmol/kg; ~25 nM) activates FX at sites of vascular injury where tissue factor is exposed and activated platelets are abundant. In principle, infusion of FXa to increase the concentration of cell surface prothrombinase at the injury site would represent a more direct approach to enhance thrombin production. However, FXa is rapidly inactivated by circulating protease inhibitors resulting in a short half-life (<1-2 min). Furthermore, FXa can activate a range of procoagulant clotting factors, possibly leading to pathological activation of coagulation 14 . These seemingly insurmountable limitations associated with the infusion of FXa have been borne out by findings in hemophilic animals 15, 16 .
Our approach to address this problem is based on knowledge of the biochemistry of zymogen activation and protease formation in the S1 peptidase clan of chymotrypsin-like serine proteases 17 . Rather than attempting to enhance enzyme function, we recently developed FXa variants (e.g., FXa I16L and FXa V17A ; numbered after chymotrypsinogen 18 ) with an impaired conformational transition from the zymogen to the active protease. In this family, cleavage of the zymogen precursor between Arg 15 -Ile 16 17 perturbs the zymogen to protease transition 1 . As a result, FXa I16L and FXa V17A have zymogen-like properties that include an immature active site, decreased sensitivity toward plasma inhibitors and poor reactivity toward other physiological ligands 1 . Notably, binding to FVa facilitates the transition to the active conformation and rescues the procoagulant activity of FXa I16L and FXa V17A , resulting in normalized thrombin generation even in the context of hemophilic plasma 1,2 . Here we report that zymogen-like FXa variants correct defective hemostasis in mouse models of HA and HB. l e t t e r s Hemophilic mice are useful models to probe the effectiveness of procoagulant therapeutics as they recapitulate aspects of the human disease. In a modified activated partial thromboplastin time (aPTT) clotting assay ( Fig. 1a) , untreated HB mice had a prolonged clotting time compared to hemostatically normal wild-type (WT) mice. Intravascular administration of human FXa I16L (hFXa I16L ; 450 µg/kg or 9.8 nmol/kg, ~100 nM) corrects the prolonged aPTT in HB mice 10 min after infusion whereas PBS has no effect. The aPTT was shortened at 2 h and returned to baseline at 24 h after infusion. Shortening of the aPTT with hFXa I16L was dose dependent, as 225 µg/kg gave an intermediate result. In contrast to hFXa I16L , administration of WT hFXa in HB mice (450 µg/kg; n = 4) did not shorten the aPTT at any time point (not shown), likely due to its extremely short half-life (<0.5 min) in mouse plasma (Fig. 1b) . The zymogen-like conformation protects hFXa I16L in mouse plasma from inhibitors and extends the half-life by a factor of 30-to 60-fold ( Fig. 1b) . Estimated ex vivo half-lives in mouse plasma are ~5-to 10-fold shorter compared to human hemophilic plasma, likely reflecting the increased activity of protease inhibitors, as previously suggested 19 . Like HB mice, there is a dose-dependent shortening of the aPTT in HA mice treated with hFXa I16L , compared to PBS-treated mice (Supplementary Fig. 1 ). Taken together, these data show that hFXa I16L has an extended halflife compared to WT hFXa and corrects the prolonged clotting time in both HA and HB mice. These latter findings indicate that sufficient amounts of FVa were generated during the coagulation assays to rescue the activity of hFXa I16L .
Safety and the possibility of uncontrolled and systemic activation of coagulation is a major concern with any procoagulant protein therapeutic. Compared to PBS-treated animals, there was no major change in levels of fibrinogen, platelets or D-dimer (fibrin degradation product) over an extended time course with hFXa I16L at 450 µg/kg ( Fig. 1c-e ). There was a transient increase in thrombin-antithrombin 10 min after infusion, which returned to baseline at 30-60 min (Fig. 1f) . Histopathological evaluation of lung, liver, kidney and spleen from HB mice infused with hFXa I16L revealed no evidence of treatment-related increases in fibrin deposition (not shown). To further evaluate the safety of hFXa I16L , we performed multiday infusion experiments in WT mice (BALB/c). Animals were injected with hFXa I16L at 450 µg/kg either once (n = 5) or twice (n = 5; injections spaced 4 h apart) daily for 3 d. Compared to pre-infusion controls or PBS-infused mice (n = 5), there were no statistically significant differences in platelets, fibrinogen, D-dimer or thrombinantithrombin levels in mice treated with hFXa I16L (data not shown). Furthermore, hFXa I16L was well tolerated, as all mice survived the multidose infusion. A contributing factor to this favorable safety profile stems from the relatively poor reactivity of hFXa I16L toward a range of physiological ligands in the absence of circulating FVa 1,2 .
To evaluate the efficacy of hFXa I16L in vivo, we monitored blood loss after a hemostatic challenge ( Fig. 2) . HB mice on the C57BL/6 ( Fig. 2a ) or BALB/c ( Supplementary Fig. 2 ) background exhibit substantial blood loss after sectioning of the distal portion of the tail compared to normal mice. Infusion of hFXa I16L in HB mice 5 min before injury reduced bleeding following tail clip in a dose-dependent manner. Treatment with the highest dose (450 µg/kg) reduced total blood loss to that seen with WT mice, whereas the effect of 225 µg/kg of hFXa I16L was intermediate; there was no significant reduction in total blood loss at 113 µg/kg ( Fig. 2a ). Similar dose response results with hFXa I16L were obtained in HA mice ( Supplementary Fig. 3 ). Infusion of a second variant (hFXa V17A ; 450 µg/kg) with similar biochemical properties as hFXa I16L into HB mice also decreased total blood loss to that obtained with normal mice (Supplementary Fig. 2) . In contrast, HB mice infused with WT hFXa (450 µg/kg) showed no improvement in blood loss compared to HB controls ( Supplementary  Fig. 2) . These data show that infusion of hFXa I16L before injury is effective in reducing blood loss in hemophilic animals after a severe hemostatic challenge.
As pro-hemostatic agents are generally administered after a bleeding episode, we next examined whether hFXa I16L can reduce bleeding when infused after an injury ( Fig. 2b) . Following tail injury and an observation period of 2 min, hFXa I16L or PBS were injected into mice by means of a jugular vein cannulus and total blood loss was monitored for an additional 10 min. Using this strategy, hFXa I16L was very effective at decreasing bleeding in HB mice: 225 µg/kg and 450 µg/kg reduced total blood loss to that seen with WT mice and with 113 µg/kg partial reduction in blood loss was seen. The increased effectiveness of hFXa I16L when administered after ( Fig. 2b) versus before ( Fig. 2a ) tail injury is likely due to inactivation of a proportion of hFXa I16L by circulating inhibitors before the injury.
Injury to the carotid artery using FeCl 3 provides another useful assay of therapeutic procoagulants. Hemophilic animals do not Figure 1 Effect of hFXa I16L on coagulation parameters. (a) HB mice (BALB/c) were injected with PBS (; n = 7) or hFXa I16L (m, 225 µg/kg, n = 4; , 450 µg/kg, n = 9). A modified onestage aPTT was performed on processed mouse plasma at the time intervals indicated. Clotting times for WT mice (, n = 7) are also indicated. (b) WT hFXa (d, 20 nM) or hFXa I16L (m, 20 nM) were incubated in diluted HB (BALB/c) mouse plasma and residual activity was assessed by clotting assay. The solid lines were drawn after analysis of data sets to a single exponential decay with fitted half-lives of 0.15 ± 0.01 min and 5.3 ± 0.46 min for WT hFXa and hFXa I16L , respectively. These values have been appropriately adjusted for sample dilution. The data are representative of two to three similar experiments. (c-f) Markers of coagulation activation. HB mice (BALB/c) were injected with PBS (; n = 3-10) or hFXa I16L (, 450 µg/kg, n = 3-8). At the indicated time intervals, levels of fibrinogen (c), platelets (d), D-dimer (e) and thrombin-antithrombin complex (TAT) (f) were measured. In a and c-f, all measurements are presented as mean ± s.e.m. For statistical comparisons, treated animals are compared to HB-PBS controls at the same time point; **, P < 0.001; *, P < 0.05. 20 . Following application of FeCl 3 (15%) to the surface of the carotid artery for 2 min, WT mice or HB mice infused with hFIX after injury present with full occlusion characterized by interruption of blood flow ( Table 1 and Supplementary Fig. 4) . In contrast, no evidence of clot formation was detected in PBS-treated HB mice. To test hFXa I16L in HB mice, FeCl 3induced injury was monitored for 10 min to ensure that blood flow remained stable. hFXa I16L was then administered through a jugular vein cannulus. Using this model, hFXa I16L rapidly induced complete vessel occlusion in all mice (n = 13) at 180-450 µg/kg ( Table 1 and Supplementary Fig. 4 ). Transient and occlusive thrombi were observed at a lower dose (90 µg/kg). A second method involved administering hFXa I16L (n = 5; 450 µg/kg) to HB mice 10 min before the application of FeCl 3 . Subsequent injury to the carotid artery resulted in complete occlusion in all five mice at 2.5 ± 1.1 min after injury (not shown). In these experiments, hFXa I16L induced vessel occlusion more rapidly (~2 min) than the rates observed in untreated control mice (~10-14 min). As infusion of hFXa I16L bypasses both the intrinsic and extrinsic pathways, the rate of thrombin formation would be expected to be much faster than in WT mice. Total blood loss (µl) b Figure 2 Blood loss following tail-clipping. (a) PBS (white column) or hFXa I16L (blue columns) was administered to HB mice (C57Bl/6) via tail vein at the indicated dosage 5 min before injury. Total blood loss (µl) was then measured after tail transection. (b) Tail clipping was performed on WT mice or HB mice (BALB/c) before protein infusion and blood was collected for 2 min (total blood loss at 2 min: WT mice: 17 ± 5.4 µl; HB: 49 ± 7.7 µl). Subsequently, PBS (white column) or hFXa I16L (blue columns) was administered to HB mice through a jugular vein cannulus at the indicated dosage; WT mice also received PBS (black column). Blood was collected for an additional 10 min in a fresh tube of saline and total blood loss (µl) was measured. Data in b represent total blood loss subsequent to protein infusion. (c) PBS (white column) or hFVIIa (red columns) was administered to HB mice (C57Bl/6) by means of tail vein at the indicated dosage 5 min before injury. Total blood loss (µl) was then measured following tail transection.
(d) PBS (white column), mFXa I16L (blue columns) or mFVIIa (red columns) was administered to HB mice (BALB/c) through tail vein at the indicated dosage 5 min before injury. Total blood loss (µl) was then measured following tail transection. In a-d, hemostatically normal mice of the appropriate strain infused with PBS (WT-PBS, black column) served as a control. In each panel, the number of animals per group is indicated and all measurements are presented as mean ± s.e.m. For statistical comparisons, treated animals are compared to HB-PBS controls. **, P < 0.001; *, P < 0.05. Figure 4 . l e t t e r s Consistent with this, introduction of hFXa I16L into a thrombin generation assay using human hemophilic plasma substantially shortens the lag time or onset of thrombin generation compared to normal plasma without added FXa 2 . Similarly, FVIIa and FEIBA also shorten the lag time in a thrombin generation assay 21 and the time to occlusion following FVIIa administration in the FeCl 3 model is comparable to that of FXa I16L ( Table 1) . The efficacy of hFXa I16L was further assessed in the microcirculation through the kinetics of thrombus formation following laser injury to arterioles in the cremaster muscle. Infusion of hFXa I16L (10 µg/kg or 0.2 nmol/kg, ~2.5 nM) 5 min before vessel injury restored platelet and fibrin accumulation at rates comparable to those observed in WT mice ( Fig. 3a and Supplementary Movies 1  and 2) . Quantitative analysis revealed that hFXa I16L -induced platelet accumulation was comparable to that observed in WT mice, whereas total fibrin deposition was reduced and slightly delayed (Fig. 3b,c) . In contrast, little, if any, accumulation of platelets or fibrin was detected in PBS-infused HB controls (Fig. 3a-c) . Thrombus formation was observed 92% and 100% of the time at 10 µg/kg (n = 3 mice, 20 injuries) and 90 µg/kg (n = 8 mice, 55 injuries), respectively. In addition, we explored the consequences of hFXa I16L infusion after laser injury. There was no detectable clot formation in HB mice following laser injury (Supplementary Movie 3) . However, subsequent infusion of hFXa I16L (30 µg/kg) through a jugular vein cannulus rapidly resulted in platelet/fibrin accumulation at the previous injury site.
Collectively, these data show that infusion of hFXa I16L either before or after laser injury restores hemostasis at the microcirculation level. hFXa I16L was effective at a much lower dose (25-to 45-fold) in this model than in the tail clip/FeCl 3 models. Although this could reflect sensitivity issues, it may result at least in part from differences in vessel size (~10-fold difference in diameter between carotid artery and arterioles), mechanism of clot formation, availability of FVa and/or the nature of the initiating injury. Differences in efficacy between tail clip/FeCl 3 and laser injury models have also been noted with FVIIa and when investigating how a variation of FV, FV-Leiden, influences the hemophilic phenotype 20, 22, 23 .
Currently, FVIIa is the only recombinant bypassing biotherapeutic approved for treatment of bleeding episodes in hemophilia inhibitor patients 3 . It is generally thought that FVIIa at pharmacological doses binds to activated platelets and converts FX to FXa in a tissue factor-independent manner, albeit at a very slow rate 24 . This likely explains the need for frequent high-dose infusions for an adequate hemostatic response 3 . The relative inefficiency of FVIIa in generating FXa at the platelet surface and the variability of procoagulant platelet populations between patients may explain the difficulty in establishing a relationship between FVIIa plasma concentration and its hemostatic effect, complicating optimal treatment 25 . Furthermore, high treatment cost and lack of clinically useful laboratory assays to monitor therapeutic responses suggest a need to compare effectiveness of other hemostatic agents to FVIIa. To begin to evaluate this, we compared the efficacy of hFXa I16L to human FVIIa (hFVIIa) using the tail clip and FeCl 3 injury models. Consistent with prior reports 26 , high levels of hFVIIa were needed to reduce blood loss following tail injury in both HB (Fig. 2c) and antibody-induced HA animals (Supplementary Fig. 5 ). For hFVIIa-treated mice, reductions in blood loss occurred at 3-5 mg/kg (60-100 nmol/kg, ~0.6-1.0 µM), representing an approximately tenfold increase in efficacy compared to hFXa I16L treatment. Similarly, high concentrations of hFVIIa (3-5 mg/kg) were needed to induce thrombus formation in HB mice in the FeCl 3 injury model ( Table 1) . Like hFXa I16L , infusion of hFVIIa following injury to the carotid artery rapidly (2.5-3.0 min) induced occlusive or transient thrombi.
Notwithstanding the compelling effectiveness of hFXa I16L relative to hFVIIa, the clinical relevance of our findings must be interpreted cautiously, as human proteins were used with the potential for suboptimal species compatibility between clotting factors. This is particularly true with hFVIIa as it binds weakly, if at all, to murine tissue factor 23, 27 . To address this point, we expressed and purified murine derivatives of FXa I16L (mFXa I16L ) and FVIIa (mFVIIa). Recombinant mFVIIa has recently been shown to be functionally similar to hFVIIa, except with respect to tissue factor binding 23, 27 . Biochemical characterization of purified mFXa I16L revealed that it has zymogen-like properties and can be rescued in assays where FVa is generated. For example, mFXa I16L has low activity (2-4%) in the absence of FVa compared to WT mFXa, as assessed by peptidyl substrate cleavage ( Supplementary Fig. 6 ), yet the variant is as effective as WT mFXa in a thrombin generation assay where FVa is generated in situ (Supplementary Fig. 7) . Consistent with its zymogen-like properties, mFXa I16L has a much longer half-life in murine HB plasma compared to that of WT mFXa. This indicates that, like hFXa I16L , it is partially protected from plasma-based inhibitors (Supplementary Fig. 8) .
The efficacy of mFXa I16L and mFVIIa in HB mice were compared using both the tail clip and FeCl 3 injury models. As expected, mFXa I16L was able to substantially reduce blood loss in the tail clip assay; interestingly the dose required for efficacy was fourfold less for mFXa I16L compared to the human protein. Only 100 µg/kg (2 nmol/kg, ~20 nM) reduced blood loss to that seen in WT mice (Fig. 2d) . Similarly, mFXa I16L was also clearly effective in the FeCl 3 injury model, with five out of eight animals presenting with full occlusion at 50-100 µg/kg ( Table 1) . In contrast, high levels of mFVIIa were needed in both the tail clip ( Fig. 2d) and FeCl 3 injury models ( Table 1) . For mFVIIa-treated mice, reductions in blood loss occurred only at 5 mg/kg, representing an ~50-fold increase in therapeutic dose compared to mFXa I16L . These within-species comparisons collectively indicate that FXa I16L is superior as a hemostatic bypass compared to FVIIa in hemophilic mice using established injury models. Although results with FXa I16L are certainly encouraging, additional parameters such as pharmacokinetic profile, dosing and safety will need to be assessed in a large animal model of hemophilia. Unlike in the mouse model, the pharmacokinetics and dosing of FVIIa in hemophilic dogs is very similar to those parameters in humans. An important question in future experimentation is whether this 10-to 50-fold dose advantage of FXa I16L versus FVIIa seen in mice translates to the hemophilic dog model.
The high dose of FVIIa needed to ameliorate the hemophilic phenotype in mice supports the notion of a dominant role for the platelet-surface, tissue factor-independent procoagulant mechanism in mediating its effects 26 . Unlike this mechanism, FXa I16L efficacy absolutely requires not only procoagulant cellular surfaces but also the availability of its cofactor, FVa. We speculate that activated platelets play a key overall role in this process as they provide the necessary procoagulant membrane surface and release relatively large quantities of FV/FVa from α-granules 25, 28 . Prior studies using isolated thrombinactivated platelets demonstrated that released platelet-derived FVa was sufficient to completely rescue the activity of hFXa I16L leading to rapid prothrombin activation 2 . The importance of activated platelets to the overall hemostatic potential of FXa I16L was seen in additional thromboelastography experiments (Supplementary Table 1) . In the absence of an added extrinsic (e.g., tissue factor) or intrinsic pathway activator, the addition of hFXa I16L with a direct platelet activator (ADP or collagen) to HB mouse whole blood completely normalized the coagulation parameters seen with hemophilic samples to values seen in normal blood. These data show that direct platelet activation with subsequent release of FV/FVa efficiently restores the activity of hFXa I16L to correct altered whole blood coagulation in the context of hemophilia.
We have exploited insights into the biochemistry of the FX zymogen to protease transition to circumvent limitations inherent to WT FXa that preclude its use as a therapeutic bypass for hemophilia. Our strategy of employing rational mutagenesis to reduce FXa function by rendering it more zymogen-like has yielded a remarkably effective agent for modulating hemostasis in hemophilic mice. The plasticity of zymogen-like FXa is central to this effectiveness, as enzyme function can be restored by FVa and activated cellular surfaces following vascular damage. This selective and localized enhancement of cell-surface prothrombinase rapidly produces thrombin at the injury site. The favorable safety profile of this variant in mice results from its extended half-life in plasma and poor reactivity toward other physiological substrates in comparison to WT FXa. Any procoagulant therapeutic has the potential for thromboembolic complications, and future studies in larger animals are needed. Furthermore, although the complexity of the immune response makes predictions difficult, it remains possible that an antibody response could be mounted against hFXa I16L despite a conservative amino acid change. Of note, evaluation of a FVIIa variant with three amino acid substitutions found no development of antibodies in a phase I clinical trail 29 . Overall, the current data with FXa I16L provide a proof of concept for a new class of bypassing agent with high hemostatic potential to treat patients with bleeding disorders. These studies also provide a general protein engineering strategy to modulate, either directly or indirectly, the activity of other serine proteases of biologic and therapeutic importance.
METhOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Note: Supplementary information is available on the Nature Biotechnology website.
ONLINE METhOdS
Reagents. All tissue culture reagents were from Invitrogen except insulintransferrin-sodium selenite which was from Roche. Human factor deficient plasmas from individual donors were purchased from George King Biomedical. Automated activated partial thromboplastin time reagent (aPTT; TriniClot or Sta-C.K.Preset) was from Tcoag or Stago. Adenosine diphosphate (ADP) and collagen (collagen fibrils, type I from equine tendons) were obtained from Chrono-log. All reagents necessary to perform rotational thromboelastography (ROTEM) were obtained from Pentapharm. Preparation and characterization of recombinant WT hFXa, hFXa I16L , hFXa V17A and mFVIIa has been previously described 1, 23 . Recombinant WT mFX and mFX I16L were expressed in human embryonic kidney 293 (HEK293) cells and prepared essentially as described 1 , except rather than employing immunopurification with an anti-FX antibody, the final purification step involved elution of mFX from a Poros HQ/20 column with a CaCl 2 gradient (0-20 mM).
Antibodies. Rat anti-mouse CD41 antibody (clone MWReg 30) prepared as a F (ab)2 fragment was from BD Bioscience. Mouse anti-human fibrin monoclonal antibody (clone 59D8), which cross-reacts with mouse fibrin, has been previously described 30, 31 . These antibodies were conjugated with Alexa 555 or Alexa 488 using the Alexa Fluor Protein Labeling Kit according to the manufacturer's instructions (Molecular Probes/Invitrogen). The mouse anti-human FVIII antibody, GMA-8015, was from Green Mountain Antibodies. Plasma levels of mouse thrombin-antithrombin (Enzygnost TAT, Dade Behring), D-dimer (Asserachrom D-Di; Diagnostica Stago) and fibrinogen (Innovative Research) were measured by enzyme-linked immunosorbent assay according to the manufacturer's guidelines.
Mice. Hemophilia B mice (BALB/c or C57BL/6) have been previously described and backcrossed for more than five generations onto the appropriate strain 32, 33 . Wild-type mice used in control experiments were either purchased from Jackson Laboratory or generated as littermates to HB mice (C57BL/6 background, heterozygous female x wild-type male breeding format). To experimentally induce an HA phenotype, C57BL/6 mice purchased from Taconic Farms were injected with an anti-FVIII antibody (GMA-8015; 4.0 mg/kg). This is an inhibitory antibody directed against the FVIII A2 domain and cross-reacts with FVIII from multiple species. For all experiments, mice were 6-10 weeks of age and weighed 20-30 g. Experimental approval was obtained from the Children's Hospital of Philadelphia and Pfizer Institutional Animal Care and Use Committee.
Coagulation assays. Blood samples from mice obtained by tail clipping were collected into one-tenth volume of 3.8% sodium citrate and immediately processed. Complete blood cell counts from individual mice were measured with an automated complete blood count analyzer with settings established for mouse blood (Hemavet, Drew Scientific). Plasma was collected from whole blood after centrifugation and samples were evaluated fresh or snap frozen and stored at -80 °C. The activated partial thromboplastin time (aPTT) on samples obtained from mice (WT or hemophilic) infused with FXa or PBS were assessed essentially as described 34 . For ex vivo half-life determinations, FXa (20 nM, final) was incubated in diluted hemophilic mouse plasma (1:4, 1:5, or 1:8) at 25 °C and at various time points aliquots of the reaction were further diluted (0.1 nM FXa, final) in 20 mM HEPES, 0.15 M NaCl, 0.1% polyethylene glycol 8000, pH 7.5 (dilution buffer). Residual FXa bypassing activity was assessed over time using a modified aPTT clotting assay. In a typical assay, 50 µl of human HB plasma was mixed with an equal volume of aPTT reagent followed by a 180 s incubation period at 37 °C. A 50 µl mixture of FXa (0.1 nM) in dilution buffer was then added to the solution and coagulation was initiated after the addition of 50 µl of 25 mM CaCl 2 . Time to clot formation was measured using a Start4 coagulation instrument (Diagnostica Stago).
Chromogenic substrate hydrolysis. All kinetic measurements were done in 20 mM HEPES, 0.15 M NaCl, 0.1% (wt/vol) PEG-8000, 2 mM CaCl 2 , pH 7.5 (assay buffer). The kinetic parameters of peptidyl substrate hydrolysis (Spectrozyme Xa; American Diagnostica) were measured using increasing concentrations of substrate (10-500 µM) and initiated with either WT mFXa (2.0 nM) or mFXa I16L (10 nM).
Rotational thromboelastography (ROTEM)
. Whole blood (300 µl) from hemostatically normal WT or HB mice (BALB/c) was collected into citrate after tail clipping. Blood was transferred to a pre-warmed (37 °C) ROTEM cup containing 0.2 M CaCl 2 (20 µl) and 20 µl of coagulation activator (INTEM reagent; ADP, 25 µM; or collagen, 30 µg/ml). Bypassing protein or PBS (2 µl) to achieve the final indicated concentration ( Supplementary Table 1 ) was immediately added. Data derived from the ROTEM machine were collected over 90 min and analyzed using the manufacturer's software.
Thrombin generation assays. Thrombin generation in platelet-poor murine plasma was determined essentially as described with some modifications due to the higher activity of coagulation inhibitors in mouse plasma 2, 19 . Briefly, normal or HB murine (BALB/c) plasma (15 µl) was mixed with a tissue-factor reagent (10 µl; Technothrombin RB; 2 pM tissue factor/4.0 µM phospholipid) followed by the addition of WT mFXa or mFXa I16L (25 µl). The reaction was immediately initiated after the addition of Z-Gly-Gly-Arg-AMC in 15 mM CaCl 2 (50 µl; 0.5 mM, final) and the concentration of thrombin (at 33 °C) was determined as described 2 .
Tail clip assay. Two different versions of the tail clip assay were employed. In the first, protein or PBS was initially infused through the tail vein ~5 min before injury. Mice were then anesthetized with isoflurane and then the tail was pre-warmed at 37 °C and the distal portion transected at a diameter of 3 mm. The tail was then placed in a conical tube containing 10 ml or 14 ml of saline at 37 °C and blood was collected for 10 min. In the second method, mice were anesthetized with isoflurane and then the tail was pre-warmed at 37 °C and the distal portion transected at a diameter of 3 mm. The tail was then placed in a conical tube containing 14 ml of saline at 37 °C and blood was collected for 2 min. Protein or PBS was then infused via a jugular vein cannulus. The injured tail was moved to a fresh tube of saline, and blood was collected for an additional 10 min. Quantitative assessment of blood loss was determined by measuring total hemoglobin by absorbance at 575 nm following red cell lysis as described 35 . For some experiments, hemoglobin content was determined using the QuantiChromTM Hemoglobin Assay Kit (BioAssay Systems). For both determinations, quantitative assessment of hemoglobin content was converted to total blood loss (µl) using appropriately established standard curves using each method.
Ferric chloride carotid artery model. Ferric chloride-induced injury was performed according to published procedures 20 . Briefly, mice were anesthetized with pentobarbital and the carotid artery was exposed. A jugular vein cannula was established to allow for infusion of proteins. A miniature Doppler flow probe (Model 0.5VB; Transonic Systems) was positioned around the exposed artery and baseline blood flow measurements were recorded. To induce an injury, a 2 mm 2 piece of Whatman #1 filter paper soaked in 15% FeCl 3 (0.92 M) was then applied to the adventitial surface of the artery for 2 min. The surface was then flushed with saline, and blood flow was continuously monitored for up to 30 min. The time to carotid artery occlusion was defined as the time following application of FeCl 3 until the blood flow has decreased by >90%. In some experiments involving HB animals, an injury was induced with FeCl 3 and blood flow was monitored for 10 min, after which defined coagulation proteins were infused through a jugular vein cannula. Blood flow was monitored for an additional 20 min. In these experiments, the time to occlusion was defined as the time from infusion of clotting factors until the blood flow decreased by 90%.
Real-time in vivo imaging of thrombus formation. Evaluation of hemostasis following laser injury to the cremaster muscle has been previously described 36 and our specific experimental system has been detailed 20, 32 . Alexa 555 -labeled rat anti-CD41 F (ab)2 and Alexa 488 -labeled anti-fibrin antibody were administered through a jugular vein cannula to label platelets and fibrin, respectively. Based on empirical studies, antibodies were infused into mice at 0.2 mg/kg for the anti-CD41 F ab fragment and 0.1 mg/kg for the antifibrin antibody. Cremasteric arterioles of 30-50 µm were selected for study
